Semi-Annual Consolidated Statement Of Comprehensive Income

ASKA Pharmaceutical Holdings CO., Ltd. - Filing #7586092

Concept 2022-04-01 to
2022-09-30
2021-04-01 to
2021-09-30
Semi-annual consolidated statement of comprehensive income
Statement of comprehensive income
Profit (loss)
2,346,000,000 JPY
-2,796,000,000 JPY
Other comprehensive income
Valuation difference on available-for-sale securities
519,000,000 JPY
162,000,000 JPY
Remeasurements of defined benefit plans, net of tax
13,000,000 JPY
15,000,000 JPY
Share of other comprehensive income of entities accounted for using equity method
371,000,000 JPY
59,000,000 JPY
Other comprehensive income
905,000,000 JPY
237,000,000 JPY
Comprehensive income
3,251,000,000 JPY
-2,559,000,000 JPY
Comprehensive income attributable to
Comprehensive income attributable to owners of parent
3,251,000,000 JPY
-2,559,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.